首页> 外文OA文献 >“Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma

【2h】

“Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma

机译：“短疗程”硼替佐米加美法仑和泼尼松作为移植前的诱导或对先前未经治疗的多发性骨髓瘤患者的非移植候选药物进行一线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Gasparetto Cristina; Gockerman Jon P.; Diehl Louis F.; de Castro Carlos M.; Moore Joseph O.; Long Gwynn D.; Horwitz Mitchell E.; Keogh George; Chute John P.; Sullivan Keith M.; Neuwirth Rachel; Davis Patricia H.; Sutton Linda M.; Anderson Russell D.; Chao Nelson J.; Rizzieri David;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. [J] . Gasparetto C, Gockerman JP, Diehl LF, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2010,第1期

机译：“短疗程”硼替佐米加美法仑和泼尼松作为移植前的诱导或对先前未经治疗的多发性骨髓瘤患者的非移植候选药物进行一线治疗。
2. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [J] . Mateos MV, Oriol A, Martinez Lopez J, The lancet oncology . 2010,第10期

机译：对于未经治疗的多发性骨髓瘤老年患者，硼替佐米，美法仑和泼尼松与硼替佐米，沙利度胺和泼尼松作为诱导疗法，然后采用硼替佐米和沙利度胺与硼替佐米和泼尼松维持治疗：一项随机试验。
3. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. [J] . Morabito F, Gentile M, Mazzone C, Blood: The Journal of the American Society of Hematology . 2011,第22期

机译：硼替佐米-美法仑-泼尼松-沙利度胺联合硼替佐米-沙利度胺维持（VMPT-VT）与硼替佐米-美法仑-泼尼松（VMP）在未经治疗的多发性骨髓瘤肾功能不全患者中的安全性和有效性。
4. HIGH-DOSE MELPHALAN CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN 65 PATIENTS WITH AL AMYLOIDOSIS: ORGAN PROGRESSION CAN BE DELAYED IN PATIENTS REACHING COMPLETE REMISSION [C] . SO Schonland, J.B Dengler, M Hundemer, International Symposium on Amyloidosis . 2008

机译：在65例Al淀粉样蛋白患者中，具有自体蛋白化疗的高剂量蛋白化疗：器官进展可以延迟达到完全缓解的患者
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Bortezomib cumulative dose efficacy and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy [O] . María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, 2014

机译：在未接受大剂量治疗的未接受治疗的骨髓瘤患者中三种不同的硼替佐米-美法仑-泼尼松方案的硼替佐米的累积剂量疗效和耐受性
7. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment [O] . Morabito F, Gentile M, Mazzone C, 2011

机译：硼替佐米-美法仑-泼尼松-沙利度胺联合硼替佐米-沙利度胺维持（VMPT-VT）与硼替佐米-美法仑-泼尼松（VMP）在未经治疗的多发性骨髓瘤肾功能不全患者中的安全性和有效性

“Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma

著录项

相似文献

相关主题

期刊订阅